Literature DB >> 23869398

The yield and cost of colonoscopy in patients with metastatic cancer of unknown primary.

M Saliminejad1, S Bemanian, A Ho, B Spiegel, L Laine.   

Abstract

BACKGROUND: Although gastroenterologists are asked to perform colonoscopy in patients with metastatic cancer of unknown primary (MCUP), studies evaluating this practice are lacking. AIM: To determine the yield and cost of colonoscopy in patients referred for colonoscopy with an indication of MCUP.
METHODS: We prospectively and retrospectively assessed colonoscopies performed from 2000 to 2011 at a county, a university, and a Veterans Administration medical centre to identify patients referred for colonoscopy for the indication of MCUP. Exclusion criteria included overt or occult bleeding, iron-deficiency anaemia, familial-colon-cancer syndrome, prior colon cancer, imaging suggesting colorectal lesion, and palpable rectal mass. Outcomes were the number of primary colon cancers and costs based on 2012 Medicare reimbursements.
RESULTS: Two (1%) of the 160 patients meeting enrollment criteria had a primary colon cancer identified, and both died within 1 month after diagnosis without receiving therapy targeted at colon cancer. One patient without colon cancer had a perforation because of colonoscopy, which required surgery and colostomy. The cost of a strategy of routinely performing colonoscopy in patients referred with MCUP was $84 736 per colon primary identified.
CONCLUSIONS: Primary colon cancer was rarely identified at colonoscopy in patients with MCUP and no standard indications for diagnostic colonoscopy. Furthermore, the cost to diagnose one additional colon primary was very high. Those with colon cancer had advanced disease and were unable to benefit from targeted therapy. Routine colonoscopy for MCUP cannot be recommended at present.
© 2013 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2013        PMID: 23869398     DOI: 10.1111/apt.12429

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  2 in total

1.  Healthcare Costs Before and After Diagnosis of Cancer of Unknown Primary Versus Ovarian Cancer in Australia.

Authors:  Louisa G Gordon; C Wood; R W Tothill; P M Webb; P Schofield; L Mileshkin
Journal:  Pharmacoecon Open       Date:  2022-10-17

2.  Cancer of unknown primary: Registered procedures compared with national integrated cancer pathway for illuminating external validity.

Authors:  Anne-Kirstine Dyrvig; Knud Bonnet Yderstræde; Oke Gerke; Peter Bjødstrup Jensen; Søren Hess; Poul Flemming Høilund-Carlsen; Anders Green
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.